Tag:
ImmusanT
Latest Headlines
Latest Headlines
Microtest to manufacture ImmusanT's celiac vaccine
Microtest Laboratories will manufacture Nexvax2 for a mid-stage trial of ImmusanT's vaccine as a treatment for celiac disease. ImmunsanT secured $20 million in venture captial funding from Vatera
ImmusanT lands $20M for celiac vaccine work
ImmusanT has won a big round of venture capital for its work on a vaccine for celiac disease. Vatera Healthcare Partners is putting up $20 million to help support clinical development of Nexvax2. A
Cambridge, MA startup snags $20M for therapeutic vaccine program
After importing the IP for a new therapeutic vaccine that promises to desensitize celiac disease patients to the toxic effects of gluten, the newly established ImmusanT has rounded up $20 million
Celiac disease vax has positive Ph1 results
Sufferers from celiac disease may get a reprieve from their gluten-free diets thanks to a vaccine currently in Phase I trials. But the vaccine won't go into Phase II until next year at the earliest,
